Royalty Pharma plc

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, VRTX has a market cap of 121.3B. Regarding current trading prices, RPRX is priced at $36.59, while VRTX trades at $472.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas VRTX's P/E ratio is -123.96. In terms of profitability, RPRX's ROE is +0.16%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, RPRX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check VRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, REGN has a market cap of 59.9B. Regarding current trading prices, RPRX is priced at $36.59, while REGN trades at $564.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas REGN's P/E ratio is 14.36. In terms of profitability, RPRX's ROE is +0.16%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RPRX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check REGN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RPRX is priced at $36.59, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RPRX's ROE is +0.16%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RPRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check SGEN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ALNY has a market cap of 42.7B. Regarding current trading prices, RPRX is priced at $36.59, while ALNY trades at $328.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ALNY's P/E ratio is -155.32. In terms of profitability, RPRX's ROE is +0.16%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, RPRX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ALNY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ARGX has a market cap of 36.2B. Regarding current trading prices, RPRX is priced at $36.59, while ARGX trades at $591.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ARGX's P/E ratio is 36.08. In terms of profitability, RPRX's ROE is +0.16%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, RPRX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ARGX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BNTX has a market cap of 27.5B. Regarding current trading prices, RPRX is priced at $36.59, while BNTX trades at $114.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BNTX's P/E ratio is -30.88. In terms of profitability, RPRX's ROE is +0.16%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, RPRX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BNTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, SMMT has a market cap of 20.5B. Regarding current trading prices, RPRX is priced at $36.59, while SMMT trades at $27.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas SMMT's P/E ratio is -81.09. In terms of profitability, RPRX's ROE is +0.16%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, RPRX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check SMMT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RPRX is priced at $36.59, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RPRX's ROE is +0.16%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RPRX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BGNE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RPRX is priced at $36.59, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.16%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, RPRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check DNA-WT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, GMAB has a market cap of 14.5B. Regarding current trading prices, RPRX is priced at $36.59, while GMAB trades at $23.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas GMAB's P/E ratio is 13.90. In terms of profitability, RPRX's ROE is +0.16%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RPRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check GMAB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, UTHR has a market cap of 13.8B. Regarding current trading prices, RPRX is priced at $36.59, while UTHR trades at $306.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas UTHR's P/E ratio is 12.20. In terms of profitability, RPRX's ROE is +0.16%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RPRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check UTHR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, RPRX is priced at $36.59, while INCY trades at $70.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas INCY's P/E ratio is 352.45. In terms of profitability, RPRX's ROE is +0.16%, compared to INCY's ROE of +0.01%. Regarding short-term risk, RPRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check INCY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MRNA has a market cap of 13.2B. Regarding current trading prices, RPRX is priced at $36.59, while MRNA trades at $34.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MRNA's P/E ratio is -3.90. In terms of profitability, RPRX's ROE is +0.16%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RPRX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MRNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RPRX is priced at $36.59, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RPRX's ROE is +0.16%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RPRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check KRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, RPRX is priced at $36.59, while EXEL trades at $44.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas EXEL's P/E ratio is 20.45. In terms of profitability, RPRX's ROE is +0.16%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, RPRX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check EXEL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, RPRX is priced at $36.59, while BMRN trades at $59.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BMRN's P/E ratio is 22.13. In terms of profitability, RPRX's ROE is +0.16%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, RPRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check BMRN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ASND has a market cap of 10.2B. Regarding current trading prices, RPRX is priced at $36.59, while ASND trades at $168.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ASND's P/E ratio is -24.93. In terms of profitability, RPRX's ROE is +0.16%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RPRX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ASND's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RPRX is priced at $36.59, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RPRX's ROE is +0.16%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RPRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RXDX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, RPRX is priced at $36.59, while TECH trades at $58.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas TECH's P/E ratio is 70.45. In terms of profitability, RPRX's ROE is +0.16%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RPRX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TECH's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, RPRX is priced at $36.59, while VRNA trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas VRNA's P/E ratio is -52.50. In terms of profitability, RPRX's ROE is +0.16%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RPRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check VRNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RPRX is priced at $36.59, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RPRX's ROE is +0.16%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RPRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check IMGN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BBIO has a market cap of 8.7B. Regarding current trading prices, RPRX is priced at $36.59, while BBIO trades at $45.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BBIO's P/E ratio is -12.83. In terms of profitability, RPRX's ROE is +0.16%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, RPRX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BBIO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RPRX is priced at $36.59, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RPRX's ROE is +0.16%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RPRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check BPMC's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RPRX is priced at $36.59, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CERE's P/E ratio is -16.47. In terms of profitability, RPRX's ROE is +0.16%, compared to CERE's ROE of -0.43%. Regarding short-term risk, RPRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check CERE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RPRX is priced at $36.59, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RPRX's ROE is +0.16%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, RPRX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ROIVW's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, RPRX is priced at $36.59, while ROIV trades at $11.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ROIV's P/E ratio is -15.17. In terms of profitability, RPRX's ROE is +0.16%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, RPRX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ROIV's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, HALO has a market cap of 7.2B. Regarding current trading prices, RPRX is priced at $36.59, while HALO trades at $58.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas HALO's P/E ratio is 15.63. In terms of profitability, RPRX's ROE is +0.16%, compared to HALO's ROE of +1.22%. Regarding short-term risk, RPRX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check HALO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, RPRX is priced at $36.59, while CORT trades at $67.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CORT's P/E ratio is 58.77. In terms of profitability, RPRX's ROE is +0.16%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, RPRX is priced at $36.59, while JAZZ trades at $118.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas JAZZ's P/E ratio is 16.03. In terms of profitability, RPRX's ROE is +0.16%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, RPRX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check JAZZ's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, RPRX is priced at $36.59, while RVMD trades at $37.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RVMD's P/E ratio is -9.28. In terms of profitability, RPRX's ROE is +0.16%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, RPRX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RVMD's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, RPRX is priced at $36.59, while IONS trades at $42.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IONS's P/E ratio is -14.10. In terms of profitability, RPRX's ROE is +0.16%, compared to IONS's ROE of -0.92%. Regarding short-term risk, RPRX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check IONS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MDGL has a market cap of 6.6B. Regarding current trading prices, RPRX is priced at $36.59, while MDGL trades at $299.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MDGL's P/E ratio is -16.78. In terms of profitability, RPRX's ROE is +0.16%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, RPRX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MDGL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RPRX is priced at $36.59, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RETA's P/E ratio is -66.29. In terms of profitability, RPRX's ROE is +0.16%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RPRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RETA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, AMRN has a market cap of 6.4B. Regarding current trading prices, RPRX is priced at $36.59, while AMRN trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas AMRN's P/E ratio is -3.53. In terms of profitability, RPRX's ROE is +0.16%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, RPRX is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check AMRN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, NUVL has a market cap of 5.9B. Regarding current trading prices, RPRX is priced at $36.59, while NUVL trades at $82.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas NUVL's P/E ratio is -18.57. In terms of profitability, RPRX's ROE is +0.16%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, RPRX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check NUVL's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, RPRX is priced at $36.59, while TGTX trades at $36.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas TGTX's P/E ratio is 146.12. In terms of profitability, RPRX's ROE is +0.16%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, RPRX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TGTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, RPRX is priced at $36.59, while RYTM trades at $87.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RYTM's P/E ratio is -31.17. In terms of profitability, RPRX's ROE is +0.16%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, RPRX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RYTM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CRSP has a market cap of 5.7B. Regarding current trading prices, RPRX is priced at $36.59, while CRSP trades at $66.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CRSP's P/E ratio is -14.72. In terms of profitability, RPRX's ROE is +0.16%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, RPRX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CRSP's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RPRX is priced at $36.59, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RPRX's ROE is +0.16%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RPRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ABCM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RPRX is priced at $36.59, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RPRX's ROE is +0.16%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RPRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ISEE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, RPRX is priced at $36.59, while AXSM trades at $104.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas AXSM's P/E ratio is -18.19. In terms of profitability, RPRX's ROE is +0.16%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, RPRX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check AXSM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, RPRX is priced at $36.59, while MRUS trades at $65.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MRUS's P/E ratio is -15.79. In terms of profitability, RPRX's ROE is +0.16%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, RPRX is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MRUS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, TLX has a market cap of 4.7B. Regarding current trading prices, RPRX is priced at $36.59, while TLX trades at $13.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas TLX's P/E ratio is 154.33. In terms of profitability, RPRX's ROE is +0.16%, compared to TLX's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check TLX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, RPRX is priced at $36.59, while PCVX trades at $36.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas PCVX's P/E ratio is -9.08. In terms of profitability, RPRX's ROE is +0.16%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RPRX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PCVX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, SLNO has a market cap of 4.6B. Regarding current trading prices, RPRX is priced at $36.59, while SLNO trades at $88.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas SLNO's P/E ratio is -18.57. In terms of profitability, RPRX's ROE is +0.16%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, RPRX is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check SLNO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $36.59, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RPRX's ROE is +0.16%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, RPRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check ALPN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CYTK has a market cap of 4.5B. Regarding current trading prices, RPRX is priced at $36.59, while CYTK trades at $37.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CYTK's P/E ratio is -7.05. In terms of profitability, RPRX's ROE is +0.16%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, RPRX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CYTK's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ABVX has a market cap of 4.4B. Regarding current trading prices, RPRX is priced at $36.59, while ABVX trades at $69.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ABVX's P/E ratio is -20.22. In terms of profitability, RPRX's ROE is +0.16%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, RPRX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ABVX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, RPRX is priced at $36.59, while ALKS trades at $26.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ALKS's P/E ratio is 12.63. In terms of profitability, RPRX's ROE is +0.16%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, RPRX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ALKS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, RPRX is priced at $36.59, while KRYS trades at $150.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas KRYS's P/E ratio is 35.88. In terms of profitability, RPRX's ROE is +0.16%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check KRYS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RPRX is priced at $36.59, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas OPT's P/E ratio is -1.52. In terms of profitability, RPRX's ROE is +0.16%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RPRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check OPT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MTSR has a market cap of 4.2B. Regarding current trading prices, RPRX is priced at $36.59, while MTSR trades at $39.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MTSR's P/E ratio is -15.66. In terms of profitability, RPRX's ROE is +0.16%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, RPRX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MTSR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ZLAB has a market cap of 4.2B. Regarding current trading prices, RPRX is priced at $36.59, while ZLAB trades at $37.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ZLAB's P/E ratio is -15.11. In terms of profitability, RPRX's ROE is +0.16%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, RPRX is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ZLAB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, RPRX is priced at $36.59, while ADMA trades at $17.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ADMA's P/E ratio is 20.61. In terms of profitability, RPRX's ROE is +0.16%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, RPRX is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ADMA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RPRX is priced at $36.59, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RPRX's ROE is +0.16%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RPRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MRTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, RPRX is priced at $36.59, while LEGN trades at $44.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas LEGN's P/E ratio is -37.47. In terms of profitability, RPRX's ROE is +0.16%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, RPRX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check LEGN's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, RPRX is priced at $36.59, while AKRO trades at $50.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas AKRO's P/E ratio is -13.46. In terms of profitability, RPRX's ROE is +0.16%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check AKRO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RNA has a market cap of 4B. Regarding current trading prices, RPRX is priced at $36.59, while RNA trades at $33.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RNA's P/E ratio is -11.07. In terms of profitability, RPRX's ROE is +0.16%, compared to RNA's ROE of -0.27%. Regarding short-term risk, RPRX is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RNA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, RPRX is priced at $36.59, while ACLX trades at $70.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ACLX's P/E ratio is -23.50. In terms of profitability, RPRX's ROE is +0.16%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, RPRX is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ACLX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, RPRX is priced at $36.59, while ACAD trades at $23.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ACAD's P/E ratio is 16.82. In terms of profitability, RPRX's ROE is +0.16%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, RPRX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ACAD's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $36.59, while VKTX trades at $33.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas VKTX's P/E ratio is -28.85. In terms of profitability, RPRX's ROE is +0.16%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, RPRX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check VKTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RPRX is priced at $36.59, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RPRX's ROE is +0.16%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RPRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check RYZB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $36.59, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RPRX's ROE is +0.16%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RPRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check CBAY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, SRRK has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $36.59, while SRRK trades at $39.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas SRRK's P/E ratio is -15.34. In terms of profitability, RPRX's ROE is +0.16%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, RPRX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check SRRK's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, PTCT has a market cap of 3.7B. Regarding current trading prices, RPRX is priced at $36.59, while PTCT trades at $46.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas PTCT's P/E ratio is 7.12. In terms of profitability, RPRX's ROE is +0.16%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, RPRX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PTCT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $36.59, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RPRX's ROE is +0.16%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RPRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check SWTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $36.59, while MLTX trades at $55.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MLTX's P/E ratio is -23.89. In terms of profitability, RPRX's ROE is +0.16%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, RPRX is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MLTX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, RPRX is priced at $36.59, while AAPG trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas AAPG's P/E ratio is -53.01. In terms of profitability, RPRX's ROE is +0.16%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RPRX is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check AAPG's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, RPRX is priced at $36.59, while PTGX trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas PTGX's P/E ratio is 68.90. In terms of profitability, RPRX's ROE is +0.16%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, RPRX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check PTGX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, RPRX is priced at $36.59, while KYMR trades at $45.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas KYMR's P/E ratio is -14.74. In terms of profitability, RPRX's ROE is +0.16%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, RPRX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check KYMR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IMVT has a market cap of 3.1B. Regarding current trading prices, RPRX is priced at $36.59, while IMVT trades at $18.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IMVT's P/E ratio is -6.71. In terms of profitability, RPRX's ROE is +0.16%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, RPRX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IMVT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $36.59, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MORF's P/E ratio is -14.88. In terms of profitability, RPRX's ROE is +0.16%, compared to MORF's ROE of -0.22%. Regarding short-term risk, RPRX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MORF's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RPRX is priced at $36.59, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MOR's P/E ratio is -12.64. In terms of profitability, RPRX's ROE is +0.16%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RPRX is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MOR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, RPRX is priced at $36.59, while CRNX trades at $30.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CRNX's P/E ratio is -8.00. In terms of profitability, RPRX's ROE is +0.16%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, RPRX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CRNX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RPRX is priced at $36.59, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RPRX's ROE is +0.16%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RPRX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check KDNY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RXRX has a market cap of 2.7B. Regarding current trading prices, RPRX is priced at $36.59, while RXRX trades at $6.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RXRX's P/E ratio is -3.48. In terms of profitability, RPRX's ROE is +0.16%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, RPRX is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RXRX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IBRX has a market cap of 2.7B. Regarding current trading prices, RPRX is priced at $36.59, while IBRX trades at $3.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IBRX's P/E ratio is -5.28. In terms of profitability, RPRX's ROE is +0.16%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, RPRX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IBRX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while NAMS trades at $23.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas NAMS's P/E ratio is -12.71. In terms of profitability, RPRX's ROE is +0.16%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, RPRX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check NAMS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RPRX's ROE is +0.16%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RPRX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check MYOV's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while MIRM trades at $52.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MIRM's P/E ratio is -32.40. In terms of profitability, RPRX's ROE is +0.16%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, RPRX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MIRM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while RARE trades at $27.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas RARE's P/E ratio is -4.68. In terms of profitability, RPRX's ROE is +0.16%, compared to RARE's ROE of -1.86%. Regarding short-term risk, RPRX is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check RARE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while CPRX trades at $21.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CPRX's P/E ratio is 13.39. In terms of profitability, RPRX's ROE is +0.16%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, RPRX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CPRX's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, RPRX is priced at $36.59, while LGND trades at $132.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas LGND's P/E ratio is -18.22. In terms of profitability, RPRX's ROE is +0.16%, compared to LGND's ROE of -0.16%. Regarding short-term risk, RPRX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check LGND's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, RPRX is priced at $36.59, while APLS trades at $20.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas APLS's P/E ratio is -11.16. In terms of profitability, RPRX's ROE is +0.16%, compared to APLS's ROE of -1.00%. Regarding short-term risk, RPRX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check APLS's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, APGE has a market cap of 2.5B. Regarding current trading prices, RPRX is priced at $36.59, while APGE trades at $41.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas APGE's P/E ratio is -11.52. In terms of profitability, RPRX's ROE is +0.16%, compared to APGE's ROE of -0.19%. Regarding short-term risk, RPRX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check APGE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, NAMSW has a market cap of 2.4B. Regarding current trading prices, RPRX is priced at $36.59, while NAMSW trades at $12.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.16%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, RPRX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check NAMSW's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, RPRX is priced at $36.59, while XENE trades at $31.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas XENE's P/E ratio is -9.63. In terms of profitability, RPRX's ROE is +0.16%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check XENE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RPRX is priced at $36.59, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RPRX's ROE is +0.16%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RPRX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check PRVB's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RPRX is priced at $36.59, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RPRX's ROE is +0.16%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, RPRX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check LBPH's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IMRA has a market cap of 2.3B. Regarding current trading prices, RPRX is priced at $36.59, while IMRA trades at $46.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IMRA's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.16%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, RPRX is less volatile compared to IMRA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IMRA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, RPRX is priced at $36.59, while AGIO trades at $39.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas AGIO's P/E ratio is 3.44. In terms of profitability, RPRX's ROE is +0.16%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, RPRX is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check AGIO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RPRX is priced at $36.59, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas DICE's P/E ratio is -21.91. In terms of profitability, RPRX's ROE is +0.16%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RPRX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check DICE's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, RPRX is priced at $36.59, while ARWR trades at $16.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas ARWR's P/E ratio is -13.11. In terms of profitability, RPRX's ROE is +0.16%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check ARWR's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, RPRX is priced at $36.59, while IDYA trades at $24.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IDYA's P/E ratio is -6.79. In terms of profitability, RPRX's ROE is +0.16%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, RPRX is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IDYA's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, MESO has a market cap of 2.2B. Regarding current trading prices, RPRX is priced at $36.59, while MESO trades at $16.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas MESO's P/E ratio is -13.69. In terms of profitability, RPRX's ROE is +0.16%, compared to MESO's ROE of -0.22%. Regarding short-term risk, RPRX is less volatile compared to MESO. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check MESO's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, RPRX is priced at $36.59, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas CALT's P/E ratio is -22.73. In terms of profitability, RPRX's ROE is +0.16%, compared to CALT's ROE of -1.67%. Regarding short-term risk, RPRX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check CALT's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, HRMY has a market cap of 2.1B. Regarding current trading prices, RPRX is priced at $36.59, while HRMY trades at $36.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas HRMY's P/E ratio is 14.01. In terms of profitability, RPRX's ROE is +0.16%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, RPRX is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for RPRX.Check HRMY's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, BEAM has a market cap of 2.1B. Regarding current trading prices, RPRX is priced at $36.59, while BEAM trades at $20.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas BEAM's P/E ratio is -4.54. In terms of profitability, RPRX's ROE is +0.16%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, RPRX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check BEAM's competition here

RPRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 20.6B. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, RPRX is priced at $36.59, while IRON trades at $60.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 14.93, whereas IRON's P/E ratio is -15.57. In terms of profitability, RPRX's ROE is +0.16%, compared to IRON's ROE of -0.23%. Regarding short-term risk, RPRX is less volatile compared to IRON. This indicates potentially lower risk in terms of short-term price fluctuations for RPRX.Check IRON's competition here